Exelixis, Inc.
https://www.exelixis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exelixis, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Exelixis’ Cabometyx R&D On Track Despite Pivotal Kidney Cancer Setback
The US firm’s Cabometyx has missed the mark in combination with Roche’s Tecentriq in a challenging kidney cancer setting, but analysts argue the setback is minimal as they highlight two major readouts coming this year.
Private Equity Firm Yellow Wood Plans Refresh For Suave Beauty, Hair Products In US, Canada
Suave hair and beauty brand getting new home in US and Canada at private equity firm Yellow Wood Partners, which plans to grow line through innovation, marketing and distribution. Unilever maintains ownership in other regions.
Threat Of Cronobacter Contamination For Powder Infant Formula Rings Clear In Latest US Recall
Reckitt's identification of Cronobacter sakazakii as contaminant in its 145,000-can Enfamil recall is latest clear statement about Cronobacter bacteria potentially disrupting supply of formula and other nutritionals distributed in powder form.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- X-Ceptor Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice